Omega‐3 fatty acids and liver disease†‡
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Fish oil has become the hot topic in nutrition and health care in general over the past few years. With any therapy that receives inordinate attention from the lay press, though, scientists and health care providers must approach this issue with a healthy dose of professional skepticism. However, contrary to previous "fads", the benefits of fish oil have a strong foundation in physiological theory and peer-reviewed scientific and clinical studies, with the most notable being efficacy in certain aspects of treating heart disease.1 Fish oil is primarily composed of omega-3 fatty acids, which, along with omega-6 fatty acids, make up the essential fatty acids. These cannot be synthesized by the human body and thus must be derived from exogenous sources. Fish, marine animals, and nuts are particularly rich in omega-3 fatty acids whereas omega-6 fatty acids are concentrated in animal products, vegetable oils, and trans-fatty acids that typify the modern Western diet. Research relevant to liver disease has recently been gaining momentum with very encouraging preliminary studies which are establishing benchmarks in the field. The manuscripts highlighted in this issue of HEPATOLOGY are 2 such studies. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; NAFLD, nonalcoholic fatty liver disease; PN, parenteral nutrition. The fat-1 transgenic mouse was first described by Kang et al. in 2004.2 Its ability to convert omega-6 to omega-3 fatty acids provided an elegant model to examine membrane composition effects independent of dietary restrictions. These animals have already been used in inflammatory and neoplastic models,3, 4 the latter by the same group that demonstrated remarkable hepatoprotection in this issue. Schmöcker et al displayed amelioration of both biochemical (ALT) and histological hepatotoxicity in the well-established model of lipopolysaccharide/galactosamine-induced hepatitis and that this effect may be attributable to inflammatory cytokine down-regulation via omega-3 fatty acid content. Indeed, if true, it is likely that this is a global anti-inflammatory effect, further supported by this group's previous work in a murine colitis model.5 However, in a limitation recognized by the authors, the selection parameters of fat-1 mice did not include important omega-3 fatty acids such as alpha-linolenic acid and docosahexaenoic acid (DHA). In addition, measuring biochemical hepatotoxicity with only ALT may be excluding an effect seen in other liver function tests (e.g., AST, bilirubin, alkaline phosphatase) or overgeneralizing a single transaminitis event to whole-organ toxicity. Characterization of cholestasis or the lack thereof in this model with bilirubin measurements might better describe the hepatic response to septic insult. Regarding cytokine level measurement in the liver, mRNA levels do not necessarily correlate to biological activity. Direct measurement, as was done in the plasma measurements, or activity assays are better markers. Also, measurement of apoptosis is better noted by direct markers of DNA damage characteristic of this process, such as terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling (TUNEL). A comparison to baseline levels of apoptosis in the liver due to normal cell turnover would be appropriate. It would be interesting to see what effect shifting the omega-6/omega-3 ratio even further toward 1:1 would have in this model. Is there a "dose-dependent" response or is there a "threshold" effect that, once achieved, stays at a plateau? It should also be noted that although the fat-1 animals showed less hepatotoxicity, it still existed to some degree. Analysis of the mechanism of this overall effect would be useful in characterizing not only an omega-3 benefit but also toward understanding inflammatory and septic liver disease. The injury that results from ischemia and subsequent reperfusion of tissue has long been known to be the source of significantly morbid and often mortal insults in cases of acute embolic/thrombotic events, traumatic wounds, and organ transplantation. As blood flow is restored, the inflammatory cascade potentiates excessive cytokine production and free radical formation, with varying degrees of tissue damage, initiation of apoptosis, and local vascular derangement. Susceptibility is largely dependent on the type of cell and its physiologic milieu. El-Badry et al. studied both of these factors in a model of liver ischemia and reperfusion, specifically examining normal versus steatotic hepatocytes (and microsteatosis versus macrosteatosis) and omega-3 fatty acid supplemented alteration of the hepatic biochemical environment. When the investigators performed analysis with dynamic intravital fluoromicroscopy, the omega-3 fatty acid–supplemented hepatosteatotic animals, as compared to those fed normal chow, demonstrated decreased microvascular dysfunction, biochemical hepatitis (AST), and inflammatory activity (Kupffer cell) after
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085
Current Clinical Applications of Ω‐6 and Ω‐3 Fatty Acids
Lee, S., Gura, K. M., Kim, S., Arsenault, D. A., Bistrian, B. R., & Puder, M. (2006) · Nutrition in Clinical Practice · doi:10.1177/0115426506021004323 · Cited by 100
Self-citation
Cited by
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 354
Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease
Spadaro, L., Magliocco, O., Spampinato, D., Piro, S., Oliveri, C., Alagona, C., Papa, G., Rabuazzo, A. M., & Purrello, F. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.003 · Cited by 293
Metabolic syndrome and liver transplantation: A review and guide to management
Watt, K. D. S., & Charlton, M. R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.040 · Cited by 245
“Fish oil has also been shown to have anti-inflammatory and anti-proliferative properties, as well as to improve hepatic steatosis [81].”
Backgroundde Meijer, V. E., Gura, K. M., Le, H. D., Meisel, J. A., & Puder, M. (2009) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607109332773 · Cited by 166
Self-citation
Metadata
- Authors
- Lee, S., Gura, K. M., & Puder, M.
- Venue
- Hepatology
- Published
- 2007-04
- Volume
- 45
- Issue
- 4
- Pages
- 841-845
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2036444048
- Cited by
- 65
- References
- 2
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.